HRP20090489T1 - Hidantoinski derivati korisni kao inhibitori metaloproteinaza - Google Patents
Hidantoinski derivati korisni kao inhibitori metaloproteinaza Download PDFInfo
- Publication number
- HRP20090489T1 HRP20090489T1 HR20090489T HRP20090489T HRP20090489T1 HR P20090489 T1 HRP20090489 T1 HR P20090489T1 HR 20090489 T HR20090489 T HR 20090489T HR P20090489 T HRP20090489 T HR P20090489T HR P20090489 T1 HRP20090489 T1 HR P20090489T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- formula
- phenoxy
- compound
- sulfonyl
- Prior art date
Links
- 229940053195 antiepileptics hydantoin derivative Drugs 0.000 title 1
- 150000001469 hydantoins Chemical class 0.000 title 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- 150000003839 salts Chemical class 0.000 claims abstract 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 4
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract 2
- -1 {4-[4-(2,2,2-trifluoroethoxy)phenoxy]piperidin-1-yl}sulfonyl Chemical group 0.000 claims 5
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- APGCFEZXDHJVGR-QGZVFWFLSA-N (5s)-5-ethyl-5-[[4-[4-(1,1,2,2,2-pentafluoroethoxy)phenoxy]piperidin-1-yl]sulfonylmethyl]imidazolidine-2,4-dione Chemical compound C1CC(OC=2C=CC(OC(F)(F)C(F)(F)F)=CC=2)CCN1S(=O)(=O)C[C@@]1(CC)NC(=O)NC1=O APGCFEZXDHJVGR-QGZVFWFLSA-N 0.000 claims 1
- CPIWFNYGPDHBTN-GOSISDBHSA-N (5s)-5-ethyl-5-[[4-[4-(2,2,2-trifluoroethoxy)phenoxy]piperidin-1-yl]sulfonylmethyl]imidazolidine-2,4-dione Chemical compound C1CC(OC=2C=CC(OCC(F)(F)F)=CC=2)CCN1S(=O)(=O)C[C@@]1(CC)NC(=O)NC1=O CPIWFNYGPDHBTN-GOSISDBHSA-N 0.000 claims 1
- GCLHHSXBTHNZIR-LJQANCHMSA-N (5s)-5-ethyl-5-[[4-[4-(2,2,3,3-tetrafluoropropoxy)phenoxy]piperidin-1-yl]sulfonylmethyl]imidazolidine-2,4-dione Chemical compound C1CC(OC=2C=CC(OCC(F)(F)C(F)F)=CC=2)CCN1S(=O)(=O)C[C@@]1(CC)NC(=O)NC1=O GCLHHSXBTHNZIR-LJQANCHMSA-N 0.000 claims 1
- PIMSLVWUPZQPML-MRXNPFEDSA-N (5s)-5-methyl-5-[[4-[4-(1,1,2,2,2-pentafluoroethoxy)phenoxy]piperidin-1-yl]sulfonylmethyl]imidazolidine-2,4-dione Chemical compound C1CC(OC=2C=CC(OC(F)(F)C(F)(F)F)=CC=2)CCN1S(=O)(=O)C[C@@]1(C)NC(=O)NC1=O PIMSLVWUPZQPML-MRXNPFEDSA-N 0.000 claims 1
- NWYAUZLEGMZWIR-GOSISDBHSA-N (5s)-5-methyl-5-[[4-[4-(2,2,3,3-tetrafluoropropoxy)phenoxy]piperidin-1-yl]sulfonylmethyl]imidazolidine-2,4-dione Chemical compound C1CC(OC=2C=CC(OCC(F)(F)C(F)F)=CC=2)CCN1S(=O)(=O)C[C@@]1(C)NC(=O)NC1=O NWYAUZLEGMZWIR-GOSISDBHSA-N 0.000 claims 1
- BRUWSFUBFQYNPG-UHFFFAOYSA-N 1-phenoxypiperidine Chemical compound C1CCCCN1OC1=CC=CC=C1 BRUWSFUBFQYNPG-UHFFFAOYSA-N 0.000 claims 1
- 102000011722 Matrix Metalloproteinase 13 Human genes 0.000 claims 1
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0427403.1A GB0427403D0 (en) | 2004-12-15 | 2004-12-15 | Novel compounds I |
| PCT/GB2005/004811 WO2006064218A1 (en) | 2004-12-15 | 2005-12-14 | Hydantoin derivatives useful as metalloproteinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090489T1 true HRP20090489T1 (hr) | 2009-10-31 |
Family
ID=34090044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090489T HRP20090489T1 (hr) | 2004-12-15 | 2009-09-15 | Hidantoinski derivati korisni kao inhibitori metaloproteinaza |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8129412B2 (el) |
| EP (1) | EP1828166B1 (el) |
| JP (1) | JP5042849B2 (el) |
| KR (1) | KR20070090921A (el) |
| CN (1) | CN101080402B (el) |
| AR (1) | AR051797A1 (el) |
| AU (1) | AU2005315459B2 (el) |
| BR (1) | BRPI0519057A2 (el) |
| CA (1) | CA2589525A1 (el) |
| CY (1) | CY1109376T1 (el) |
| DE (1) | DE602005015617D1 (el) |
| DK (1) | DK1828166T3 (el) |
| ES (1) | ES2328836T3 (el) |
| GB (1) | GB0427403D0 (el) |
| HK (1) | HK1108435A1 (el) |
| HR (1) | HRP20090489T1 (el) |
| IL (1) | IL183590A0 (el) |
| MX (1) | MX2007006744A (el) |
| NO (1) | NO20073550L (el) |
| NZ (1) | NZ555684A (el) |
| PL (1) | PL1828166T3 (el) |
| PT (1) | PT1828166E (el) |
| RS (1) | RS51193B (el) |
| RU (1) | RU2388758C2 (el) |
| SA (1) | SA05260406B1 (el) |
| SI (1) | SI1828166T1 (el) |
| TW (1) | TW200634001A (el) |
| UA (1) | UA89067C2 (el) |
| WO (1) | WO2006064218A1 (el) |
| ZA (1) | ZA200705068B (el) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0818006B8 (pt) | 2007-10-19 | 2021-05-25 | Boehringer Ingelheim Int | compostos de piperidino-di-hidrotienopirimidinas substituídas, uso dos mesmos e formulações farmacêuticas |
| WO2009138777A1 (en) * | 2008-05-12 | 2009-11-19 | Astrazeneca Ab | Process for the preparation of alkoxy-phenoxy-pi peridine |
| US7759512B2 (en) | 2008-07-21 | 2010-07-20 | 3M Innovative Properties Company | Aqueous methods for making fluorinated sulfonate esters |
| CN102234287B (zh) | 2010-04-26 | 2015-08-05 | 上海阳帆医药科技有限公司 | 硝基咪唑类化合物、其制备方法和用途 |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| MY167881A (en) | 2010-07-16 | 2018-09-26 | Abbvie Bahamas Ltd | Process for preparing antiviral compounds |
| MX338725B (es) | 2010-07-16 | 2016-04-28 | Abbvie Bahamas Ltd | Ligando de fosfina para reacciones cataliticas. |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| HUP1300139A2 (en) | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| US20160364553A1 (en) * | 2015-06-09 | 2016-12-15 | Intel Corporation | System, Apparatus And Method For Providing Protected Content In An Internet Of Things (IOT) Network |
| GB201610056D0 (en) * | 2016-06-09 | 2016-07-27 | Galapagos Nv And Laboratoires Servier Les | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9919776D0 (en) * | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| JP2003501414A (ja) * | 1999-06-04 | 2003-01-14 | アストラゼネカ・アクチエボラーグ | メタロプロテイナーゼの阻害剤 |
| WO2001062742A1 (en) * | 2000-02-21 | 2001-08-30 | Astrazeneca Ab | Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases |
| SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| SE0301922D0 (sv) | 2003-06-27 | 2003-06-27 | Astrazeneca Ab | Novel compounds |
-
2004
- 2004-12-15 GB GBGB0427403.1A patent/GB0427403D0/en not_active Ceased
-
2005
- 2005-12-14 PT PT05818265T patent/PT1828166E/pt unknown
- 2005-12-14 CA CA002589525A patent/CA2589525A1/en not_active Abandoned
- 2005-12-14 CN CN2005800432057A patent/CN101080402B/zh not_active Expired - Fee Related
- 2005-12-14 NZ NZ555684A patent/NZ555684A/en not_active IP Right Cessation
- 2005-12-14 KR KR1020077013343A patent/KR20070090921A/ko not_active Application Discontinuation
- 2005-12-14 AU AU2005315459A patent/AU2005315459B2/en not_active Ceased
- 2005-12-14 RS RSP-2009/0397A patent/RS51193B/sr unknown
- 2005-12-14 PL PL05818265T patent/PL1828166T3/pl unknown
- 2005-12-14 UA UAA200706159A patent/UA89067C2/ru unknown
- 2005-12-14 SI SI200530774T patent/SI1828166T1/sl unknown
- 2005-12-14 ES ES05818265T patent/ES2328836T3/es active Active
- 2005-12-14 DK DK05818265T patent/DK1828166T3/da active
- 2005-12-14 BR BRPI0519057-6A patent/BRPI0519057A2/pt not_active IP Right Cessation
- 2005-12-14 EP EP05818265A patent/EP1828166B1/en active Active
- 2005-12-14 DE DE602005015617T patent/DE602005015617D1/de active Active
- 2005-12-14 SA SA05260406A patent/SA05260406B1/ar unknown
- 2005-12-14 WO PCT/GB2005/004811 patent/WO2006064218A1/en active Application Filing
- 2005-12-14 JP JP2007546173A patent/JP5042849B2/ja not_active Expired - Fee Related
- 2005-12-14 US US11/793,358 patent/US8129412B2/en not_active Expired - Fee Related
- 2005-12-14 MX MX2007006744A patent/MX2007006744A/es active IP Right Grant
- 2005-12-14 RU RU2007121222/04A patent/RU2388758C2/ru not_active IP Right Cessation
- 2005-12-15 TW TW094144382A patent/TW200634001A/zh unknown
- 2005-12-15 AR ARP050105275A patent/AR051797A1/es not_active Application Discontinuation
-
2007
- 2007-05-31 IL IL183590A patent/IL183590A0/en unknown
- 2007-06-12 ZA ZA200705068A patent/ZA200705068B/xx unknown
- 2007-07-09 NO NO20073550A patent/NO20073550L/no not_active Application Discontinuation
-
2008
- 2008-03-04 HK HK08102383.3A patent/HK1108435A1/xx not_active IP Right Cessation
-
2009
- 2009-09-15 HR HR20090489T patent/HRP20090489T1/hr unknown
- 2009-09-17 CY CY20091100960T patent/CY1109376T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090489T1 (hr) | Hidantoinski derivati korisni kao inhibitori metaloproteinaza | |
| US11312698B2 (en) | Fosnetupitant chloride hydrochloride having improved stability | |
| JP4346243B2 (ja) | プロトン・ポンプ・インヒビターのプロドラッグ | |
| NO2015020I1 (no) | Ceritinib, 5-klor-N-5-metyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oksy]fenyl-N-[2-(propan-2-sulfonyl)fenyl]pyrimidine-2,4-diamin, eller et farmasøytisk akseptabelt salt derav | |
| AR056582A1 (es) | COMPUESTOS DE PIRAZOLIL UREA CON ACTIVIDAD INHIBITORIA DE CINASA P38 Y FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE | |
| MEP51408A (en) | Selected cgrp antagonists, method for production and use thereof as medicament | |
| PE20050690A1 (es) | Derivados de indazol como inhibidores de la lipasa sensible a hormonas | |
| JP2002516325A (ja) | 新規な置換イミダゾール化合物 | |
| NO20076450L (no) | Heterosykliske forbindelser som nikotinsyrereseptoragonister for behandling av dyslipidemi | |
| RS52397B (en) | PYRIDO / 2,1-A / ISOCHINOLINE DERIVATIVES AS DPP-IV INHIBITORS | |
| AR053770A1 (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2. composiciones farmaceuticas. | |
| ME01111B (me) | Triazinska jedinjenja kao inhibitori p13 kinaze i mtor | |
| EA200501327A1 (ru) | Пиримидины и триазины, ингибирующие вич репликацию | |
| PE20060298A1 (es) | Derivados de acido carboxilico de bencimidazolona | |
| NO20091590L (no) | Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer | |
| NO20092341L (no) | Substituerte piperidiner inneholdende et heteroarylamid eller en heteroarylfenyl gruppe | |
| AR054045A1 (es) | Compuestos benzoimidazol sustituidos con actividad dual no inhibitoria y mu opioide agonista | |
| SK283306B6 (sk) | Benzamidínové deriváty substituované aminokyselinovými alebo hydroxykyselinovými derivátmi, farmaceutický prostriedok obsahujúci tieto deriváty a ich použitie | |
| AR058128A1 (es) | Compuesto de pirazolil carbamato y formulacion farmaceutica que lo comprende | |
| SE0400850D0 (sv) | Novel Compounds | |
| EA200401519A1 (ru) | N- ациламинобензольные производные в качестве селективных ингибиторов моноаминооксидазы b | |
| PE20060696A1 (es) | Inhibidores de la adenilato ciclasa soluble | |
| AU2003231359B2 (en) | Piperidine derivatives having CCR3 antagonism | |
| ATE532516T1 (de) | Verfahren zur synthese von glyt-1-hemmern | |
| US9403772B2 (en) | 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator |